Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates
Portfolio Pulse from
Pacific Biosciences of California (PACB) reported a Q3 loss of $0.17 per share, which was better than the expected loss of $0.20 per share. However, the company missed revenue estimates.
November 08, 2024 | 12:30 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Pacific Biosciences reported a Q3 loss of $0.17 per share, better than the expected $0.20 loss, but missed revenue estimates.
The better-than-expected EPS loss is a positive sign, but missing revenue estimates could offset this. The stock may see mixed reactions as investors weigh these factors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100